[Buserelin therapy in postmenopausal patients with advanced breast carcinoma].
Twenty-seven postmenopausal women with advanced breast cancer were treated with the potent LHRH-agonist buserelin. The drug was given s.c. three times daily at a daily dosage of 3 mg the first week and subsequently of 2 mg daily. Although pituitary gonadotropins were suppressed in all cases, no response was observed in 26 evaluable patients. This study does not confirm earlier findings suggesting a role for LHRH-agonists in the treatment of postmenopausal patients with breast cancer.
Vici
P
P
Divisione Oncologia Medica II, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma.
Veltri
E
E
Carpano
S
S
Di Lauro
L
L
Lopez
M
M
D000305:Adrenal Cortex Hormones / Q000097:blood; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D002064:Buserelin / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood; D013963:Thyroid Hormones / Q000097:blood
D000305:Adrenal Cortex Hormones; D013963:Thyroid Hormones; D013739:Testosterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin
Terapia con buserelin in pazienti in postmenopausa con carcinoma mammario in fase avanzata.